Nuveen
GLUE icon

Nuveen’s Monte Rosa Therapeutics GLUE Stock Holding History

Nuveen’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.04M Buy
166,758
+45,886
+38% +$867K ﹤0.01% 2210
2026
Q1 		$1.99M Sell
120,872
-164,987
-58% -$3.16M ﹤0.01% 2283
2025
Q4 		$4.48M Buy
285,859
+182,891
+178% +$2.46M ﹤0.01% 1956
2025
Q3 		$763K Hold
102,968
– – ﹤0.01% 2743
2025
Q2 		$464K Sell
102,968
-14,704
-12% -$65.6K ﹤0.01% 2910
2025
Q1 		$546K Buy
117,672
+14,837
+14% +$91K ﹤0.01% 2880
2024
Q4 		$714K Hold
102,835
– – ﹤0.01% 2848
2024
Q3 		$545K Buy
102,835
+13,739
+15% +$69.3K ﹤0.01% 2986
2024
Q2 		$333K Hold
89,096
– – ﹤0.01% 3122
2024
Q1 		$628K Hold
89,096
– – ﹤0.01% 2893
2023
Q4 		$503K Sell
89,096
-64,747
-42% -$254K ﹤0.01% 3001
2023
Q3 		$737K Buy
153,843
+12,815
+9% +$82.5K ﹤0.01% 2699
2023
Q2 		$966K Buy
141,028
+29,379
+26% +$190K ﹤0.01% 2677
2023
Q1 		$870K Sell
111,649
-7,149
-6% -$49.7K ﹤0.01% 2656
2022
Q4 		$905K Sell
118,798
-13,849
-10% -$115K ﹤0.01% 2720
2022
Q3 		$1.08M Sell
132,647
-2,128
-2% -$19.5K ﹤0.01% 2721
2022
Q2 		$1.3M Buy
134,775
+70,891
+111% +$712K ﹤0.01% 2673
2022
Q1 		$802K Buy
63,884
+38,595
+153% +$536K ﹤0.01% 2883
2021
Q4 		$444K Buy
25,289
+8,535
+51% +$179K ﹤0.01% 3099
2021
Q3 		$373K Buy
+16,754
New +$480K ﹤0.01% 3221

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's GLUE Position: Q2 2026 in Review

Nuveen increased its Monte Rosa Therapeutics (GLUE) stake by 38% in Q2 2026, buying an estimated $867K and bringing the position to 166,758 shares worth $4.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2210.

Nuveen first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. The position peaked at $4.48M in Q4 2025. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Nuveen held 166,758 shares of Monte Rosa Therapeutics worth $4.04M as of Q2 2026.
  • Nuveen bought 45,886 Monte Rosa Therapeutics shares in Q2 2026, an estimated $867K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2210 holding.
  • Nuveen first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Nuveen's Monte Rosa Therapeutics position peaked at $4.48M in Q4 2025.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.